ABMed Bénin: Orders Retrait of ASMOXIME-200 Lot MOTJV2405

• ABMed has ordered the immediate recall of ASMOXIME-200 antibiotic lot MOTJV2405 in Benin, effective November 3, 2026.
• The recall is due to non-compliant dosage assay results for the active substance, cefixime 200 mg, during quality control tests.
• Pharmaceutical establishments and healthcare facilities are mandated to withdraw the product and return it to wholesale distributors.
• The recalled ASMOXIME-200 is manufactured by ASMOH Laboratories Ltd. and presented as film-coated tablets in boxes of 10.
• Patients and healthcare professionals are advised to check lot numbers on their ASMOXIME-200 boxes and exercise vigilance.

The Agence béninoise du médicament et des autres produits de santé (ABMed) has initiated a critical health alert, ordering the immediate withdrawal of a specific batch of the antibiotic ASMOXIME-200 from circulation across Benin.

The Agence béninoise du médicament et des autres produits de santé (ABMed) has initiated a critical health alert, ordering the immediate withdrawal of a specific batch of the antibiotic ASMOXIME-200 from circulation across Benin. This significant directive, issued on November 3, 2026, specifically targets lot number MOTJV2405 of the medication. The ABMed retrait lot ASMOXIME-200 Bénin mandate requires all pharmaceutical establishments and healthcare facilities throughout the nation to promptly remove any affected boxes from their inventories.

This particular ASMOXIME-200 rappel Bénin pertains to a product manufactured by ASMOH Laboratories Ltd. The antibiotic, formulated with 200 mg of cefixime, is supplied as film-coated tablets in boxes containing 10 units. The comprehensive nature of this recall underscores ABMed's unwavering commitment to upholding the highest standards of safety and efficacy for all pharmaceutical products accessible to the Beninese populace, ensuring public trust in the healthcare system.

The impetus for the lot MOTJV2405 retrait stems from serious findings uncovered during routine quality control assessments. ABMed's thorough investigations revealed a significant non-conformity with the established technical specifications governing the product's composition. Crucially, laboratory tests conducted to assay the active substance within the ASMOXIME-200 lot MOTJV2405 yielded results that deviated from the required dosage standards.

This non-conformité céfixime Bénin indicates that the actual concentration of the active pharmaceutical ingredient may not align with the stated amount, thereby posing potential risks to the medication's therapeutic effectiveness or patient safety. Such discrepancies are regarded with utmost gravity by regulatory authorities, as they can directly compromise patient treatment outcomes and broader public health initiatives. The Agence béninoise du médicament alerte serves as a stark reminder of the imperative for stringent adherence to manufacturing and quality control protocols across the pharmaceutical industry.

In light of these critical findings, Yossounon Chabi, the Director General of ABMed, has issued explicit instructions to all pharmaceutical establishments and healthcare facilities. These entities are mandated to promptly remove the implicated lot from their existing stock and, furthermore, are directed to return the affected boxes without delay to their respective wholesale distributors. This procedural step is vital for facilitating the appropriate management, quarantine, and eventual disposal of the non-compliant medication.

Compliance with this ASMOH Laboratories Ltd rappel is not merely a recommendation but a compulsory requirement designed to safeguard public health and uphold the integrity of the pharmaceutical supply chain within Benin. The established process aims for swift and efficient execution, thereby minimizing any potential ongoing risk to patients who might otherwise receive or consume the substandard product.

Beyond the immediate operational actions demanded from pharmaceutical and healthcare providers, ABMed has also extended a crucial call for heightened vigilance among both patients and healthcare professionals throughout the country. Individuals who currently possess ASMOXIME-200 are strongly urged to meticulously inspect the lot number printed on their medication boxes. Should the lot number precisely match MOTJV2405, they are advised to immediately consult their healthcare provider for further guidance and appropriate action.

This proactive advisory is designed to prevent any continued use of the non-compliant antibiotic by the general public, ensuring that no patient inadvertently consumes a potentially ineffective or unsafe product. The Agence béninoise du médicament alerte underscores the significant role that informed consumer awareness plays in supporting regulatory efforts aimed at guaranteeing medication safety. The collaborative engagement of all stakeholders remains paramount in effectively managing the implications of this product recall.

Compliance officers and legal counsel for pharmaceutical establishments, distributors, and healthcare facilities in Benin must immediately ensure their organizations comply with the ABMed's recall order for ASMOXIME-200 lot MOTJV2405 to avoid regulatory penalties and potential liability for distributing non-compliant medication. They should verify stock, initiate returns, and update internal compliance protocols.

Source: Original reporting via ABMed public alert